Last reviewed · How we verify
Actonel (Risedronate)
Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity.
Risedronate inhibits bone resorption by binding to hydroxyapatite on bone surfaces and inhibiting osteoclast activity. Used for Osteoporosis in postmenopausal women, Paget's disease of bone, Glucocorticoid-induced osteoporosis.
At a glance
| Generic name | Actonel (Risedronate) |
|---|---|
| Also known as | Risedronate Sodium, Actonel |
| Sponsor | M.D. Anderson Cancer Center |
| Drug class | Bisphosphonate |
| Target | Hydroxyapatite (bone mineral); osteoclast function inhibition |
| Modality | Small molecule |
| Therapeutic area | Bone metabolism / Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Risedronate is a bisphosphonate that localizes to sites of bone resorption and directly inhibits osteoclast function, reducing bone turnover. By suppressing osteoclast-mediated bone resorption, it increases bone mineral density and reduces fracture risk in conditions characterized by accelerated bone loss.
Approved indications
- Osteoporosis in postmenopausal women
- Paget's disease of bone
- Glucocorticoid-induced osteoporosis
- Bone metastases (supportive care)
Common side effects
- Gastrointestinal irritation (esophageal irritation, dyspepsia)
- Musculoskeletal pain
- Headache
- Atypical femoral fracture (rare)
- Osteonecrosis of the jaw (rare)
Key clinical trials
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric Surgery (PHASE3)
- Rise & Renew: Supporting Well-Being in Black Women After the Loss of a Loved One (NA)
- Effects of Bisphosphonates on OI-Related Hearing Loss (PHASE4)
- Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis (NA)
- Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis Women (PHASE4)
- Denosumab Safety Assessment in Multiple Observational Databases
- A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Actonel (Risedronate) CI brief — competitive landscape report
- Actonel (Risedronate) updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI